MARKSANS PHARMA Latest Share Price (MARKSANS)
TODAY IN ONE LINE
MARKSANS fell 1.2% on light volume, in line with Nifty's -0.5% move.
With a market cap of ₹13,594.91 Cr., it trades at a P/E of 26.32. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
MARKSANS PHARMA flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 63.5% YoY
- ●High Capital EfficiencyROCE of 19.3% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 18.2%
- ●Healthy Operating MarginsOPM is structurally strong at 29.3%
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●FII AccumulationFII holding increased by 1.59% QoQ
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Rising Receivables vs SalesReceivables grew 45.2% outpacing sales growth of 20.5%
Latest MARKSANS PHARMA News
What changed recently?
Recent events, corporate actions, and announcements.
MARKSANS PHARMA valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for MARKSANS PHARMA, framed against the sector median so the premium or discount is obvious at a glance.
MARKSANS PHARMA trades at a P/E of 26.32× and P/B of 4.50×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
MARKSANS PHARMA technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for MARKSANS PHARMA — derived from the latest tape, not yesterday's close.
MARKSANS PHARMA last traded at ₹294.45 with an intraday range of ₹291.25–₹298 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹294.45| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 311.38 | +16.93 | +5.75% |
| R3 | 304.63 | +10.18 | +3.46% |
| R2 | 301.32 | +6.87 | +2.33% |
| R1 | 297.88 | +3.43 | +1.17% |
| PIVOT | 294.57 | 0.12 | 0.04% |
| CURRENT | 294.45 | — | — |
| S1 | 291.13 | -3.32 | -1.13% |
| S2 | 287.82 | -6.63 | -2.25% |
| S3 | 284.38 | -10.07 | -3.42% |
| S4 | 277.63 | -16.82 | -5.71% |
MARKSANS is trading Below CPR, indicating Bearishness
CPR is Narrower, suggesting likely for trending moves
Day's range: ₹291.45–₹297.05
Trading Inside opening range
MARKSANS PHARMA financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for MARKSANS PHARMA — consolidated or standalone — with margins, YoY growth and key ratios inline.
MARKSANS PHARMA reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹13,594.91 Cr. and reported EPS of ₹3.47.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 2,951 | 2,951 ▲ 0.0% |
| Sales Growth YoY %Derived | 1,025.09% | 1,025.09% |
| Other Income | 83 | 83 ▲ 0.0% |
| Total Income | 3,033 | 3,033 ▲ 0.0% |
| 1,277 | 1,277 ▲ 0.0% | |
| Gross ProfitDerived | 1,674 | 1,674 ▲ 0.0% |
| Gross Margin %Derived | 56.72% | 56.72% |
| 1,073 | 1,073 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 601 | 601 ▲ 0.0% |
| OPM %Derived | 20.36% | 20.36% |
| 123 | 123 ▲ 0.0% | |
| Profit Before Tax (PBT) | 561 | 561 ▲ 0.0% |
| 140 | 140 ▲ 0.0% | |
| Effective Tax %Derived | 25.06% | 25.06% |
| Total Profit for Period | 420 | 420 ▲ 0.0% |
| Less: Non-controlling Interests | 2 | 2 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 418 | 418 ▲ 0.0% |
| Net Profit Margin %Derived | 14.16% | 14.16% |
| PAT Growth YoY %Derived | 992.21% | 992.21% |
| Earnings Per Share (EPS ₹) | 9.22 | 9.22 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 45 | 45 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 176 | 176 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 2,473 | 2,473 ▲ 0.0% |
| Material Cost % of RevenueDerived | 32.51% | 32.51% |
| Employee Cost % of RevenueDerived | 14.26% | 14.26% |
| Other Cost % of RevenueDerived | 22.09% | 22.09% |
| Interest Coverage (x)Derived | 20.81x | 20.81x |
| Period | Mar 2018 | Jul 2018 | Mar 2019 | Jun 2019 | Mar 2020 | Jun 2020 | Mar 2021 | May 2021 | Mar 2022 | May 2022 | Mar 2023 | May 2023 | Mar 2024 | May 2024 | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 767 | 767 ▲ 0.0% | 1,000 ▲ 30.4% | 1,000 ▲ 0.0% | 1,134 ▲ 13.4% | 1,134 ▲ 0.0% | 1,376 ▲ 21.3% | 1,376 ▲ 0.0% | 1,491 ▲ 8.3% | 1,491 ▲ 0.0% | 1,852 ▲ 24.2% | 1,852 ▲ 0.0% | 2,177 ▲ 17.6% | 2,177 ▲ 0.0% | 262 ▼ 88.0% | 262 ▲ 0.0% | 2,951 ▲ 1025.1% | 2,951 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | 30.36% | — | 13.41% | 13.41% | 21.33% | — | 8.33% | 8.33% | 24.23% | 24.23% | 17.56% | 17.56% | -87.95% | -87.95% | 1,025.09% | 1,025.09% | |
| Other Income | 7 | 7 ▲ 0.0% | 5 ▼ 34.2% | 5 ▲ 0.0% | 0 ▼ 92.9% | 0 ▲ 0.0% | 7 ▲ 1940.9% | 7 ▲ 0.0% | 42 ▲ 525.2% | 42 ▲ 0.0% | 59 ▲ 41.7% | 59 ▲ 0.0% | 50 ▼ 15.0% | 50 ▲ 0.0% | 7 ▼ 86.0% | 7 ▲ 0.0% | 83 ▲ 1072.7% | 83 ▲ 0.0% | |
| Total Income | 774 | 774 ▲ 0.0% | 1,005 ▲ 29.8% | 1,005 ▲ 0.0% | 1,135 ▲ 12.9% | 1,135 ▲ 0.0% | 1,383 ▲ 21.9% | 1,383 ▲ 0.0% | 1,533 ▲ 10.8% | 1,533 ▲ 0.0% | 1,911 ▲ 24.7% | 1,911 ▲ 0.0% | 2,228 ▲ 16.6% | 2,228 ▲ 0.0% | 269 ▼ 87.9% | 269 ▲ 0.0% | 3,033 ▲ 1026.3% | 3,033 ▲ 0.0% | |
459 | 459 ▲ 0.0% | 498 ▲ 8.6% | 498 ▲ 0.0% | 545 ▲ 9.4% | 545 ▲ 0.0% | 595 ▲ 9.2% | 595 ▲ 0.0% | 717 ▲ 20.5% | 717 ▲ 0.0% | 921 ▲ 28.5% | 921 ▲ 0.0% | 1,038 ▲ 12.7% | 1,038 ▲ 0.0% | 114 ▼ 89.0% | 114 ▲ 0.0% | 1,277 ▲ 1016.8% | 1,277 ▲ 0.0% | ||
| Gross ProfitDerived | 308 | 308 ▲ 0.0% | 502 ▲ 62.8% | 502 ▲ 0.0% | 589 ▲ 17.4% | 589 ▲ 0.0% | 781 ▲ 32.5% | 781 ▲ 0.0% | 774 ▼ 0.9% | 774 ▲ 0.0% | 931 ▲ 20.3% | 931 ▲ 0.0% | 1,139 ▲ 22.4% | 1,139 ▲ 0.0% | 148 ▼ 87.0% | 148 ▲ 0.0% | 1,674 ▲ 1031.5% | 1,674 ▲ 0.0% | |
| Gross Margin %Derived | 40.20% | 40.20% | 50.20% | 50.20% | 51.96% | 51.96% | 56.76% | 56.76% | 51.92% | 51.92% | 50.25% | 50.25% | 52.32% | 52.32% | 56.39% | 56.39% | 56.72% | 56.72% | |
264 | 264 ▲ 0.0% | 370 ▲ 40.3% | 370 ▲ 0.0% | 397 ▲ 7.3% | 397 ▲ 0.0% | 442 ▲ 11.2% | 442 ▲ 0.0% | 515 ▲ 16.7% | 515 ▲ 0.0% | 591 ▲ 14.8% | 591 ▲ 0.0% | 681 ▲ 15.1% | 681 ▲ 0.0% | 95 ▼ 86.0% | 95 ▲ 0.0% | 1,073 ▲ 1028.8% | 1,073 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 45 | 45 ▲ 0.0% | 132 ▲ 195.3% | 132 ▲ 0.0% | 192 ▲ 45.5% | 192 ▲ 0.0% | 340 ▲ 76.6% | 340 ▲ 0.0% | 259 ▼ 23.8% | 259 ▲ 0.0% | 339 ▲ 31.1% | 339 ▲ 0.0% | 459 ▲ 35.1% | 459 ▲ 0.0% | 53 ▼ 88.5% | 53 ▲ 0.0% | 601 ▲ 1036.5% | 601 ▲ 0.0% | |
| OPM %Derived | 5.83% | 5.83% | 13.21% | 13.21% | 16.95% | 16.95% | 24.68% | 24.68% | 17.36% | 17.36% | 18.32% | 18.32% | 21.06% | 21.06% | 20.16% | 20.16% | 20.36% | 20.36% | |
37 | 37 ▲ 0.0% | 32 ▼ 12.0% | 32 ▲ 0.0% | 35 ▲ 9.1% | 35 ▲ 0.0% | 44 ▲ 24.7% | 44 ▲ 0.0% | 53 ▲ 20.6% | 53 ▲ 0.0% | 61 ▲ 14.6% | 61 ▲ 0.0% | 85 ▲ 40.2% | 85 ▲ 0.0% | 10 ▼ 88.9% | 10 ▲ 0.0% | 123 ▲ 1191.6% | 123 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 15 | 15 ▲ 0.0% | 104 ▲ 600.1% | 104 ▲ 0.0% | 157 ▲ 50.7% | 157 ▲ 0.0% | 302 ▲ 92.2% | 302 ▲ 0.0% | 248 ▼ 18.1% | 248 ▲ 0.0% | 338 ▲ 36.4% | 338 ▲ 0.0% | 424 ▲ 25.4% | 424 ▲ 0.0% | 50 ▼ 88.1% | 50 ▲ 0.0% | 561 ▲ 1012.3% | 561 ▲ 0.0% | |
4 | 4 ▲ 0.0% | 24 ▲ 569.9% | 24 ▲ 0.0% | 36 ▲ 52.6% | 36 ▲ 0.0% | 64 ▲ 74.7% | 64 ▲ 0.0% | 61 ▼ 4.6% | 61 ▲ 0.0% | 72 ▲ 19.2% | 72 ▲ 0.0% | 109 ▲ 50.2% | 109 ▲ 0.0% | 12 ▼ 88.8% | 12 ▲ 0.0% | 140 ▲ 1057.8% | 140 ▲ 0.0% | ||
| Effective Tax %Derived | 23.92% | 23.92% | 22.88% | 22.88% | 23.17% | 23.17% | 21.06% | 21.06% | 24.52% | 24.52% | 21.42% | 21.42% | 25.65% | 25.65% | 24.08% | 24.08% | 25.06% | 25.06% | |
| Total Profit for Period | 11 | 11 ▲ 0.0% | 80 ▲ 609.6% | 80 ▲ 0.0% | 121 ▲ 50.1% | 121 ▲ 0.0% | 239 ▲ 97.5% | 239 ▲ 0.0% | 187 ▼ 21.7% | 187 ▲ 0.0% | 265 ▲ 42.0% | 265 ▲ 0.0% | 315 ▲ 18.7% | 315 ▲ 0.0% | 38 ▼ 87.8% | 38 ▲ 0.0% | 420 ▲ 997.9% | 420 ▲ 0.0% | |
| Less: Non-controlling Interests | — | — | 4 | 4 ▲ 0.0% | — ▼ 100.0% | — | — | — | — | — | — | — | 1 | 1 ▲ 0.0% | — ▼ 100.0% | — | 2 | 2 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 11 | 11 ▲ 0.0% | 76 ▲ 574.6% | 76 ▲ 0.0% | 121 ▲ 57.9% | 121 ▲ 0.0% | 239 ▲ 97.5% | 239 ▲ 0.0% | 187 ▼ 21.7% | 187 ▲ 0.0% | 265 ▲ 42.0% | 265 ▲ 0.0% | 314 ▲ 18.3% | 314 ▲ 0.0% | 38 ▼ 87.8% | 38 ▲ 0.0% | 418 ▲ 992.2% | 418 ▲ 0.0% | |
| Net Profit Margin %Derived | 1.48% | 1.48% | 7.65% | 7.65% | 10.65% | 10.65% | 17.33% | 17.33% | 12.53% | 12.53% | 14.33% | 14.33% | 14.42% | 14.42% | 14.59% | 14.59% | 14.16% | 14.16% | |
| PAT Growth YoY %Derived | — | — | 574.56% | — | 57.93% | 57.93% | 97.54% | — | -21.68% | -21.68% | 42.02% | 42.02% | 18.33% | 18.33% | -87.81% | -87.81% | 992.21% | 992.21% | |
| Earnings Per Share (EPS ₹) | 0.28 | 0.28 ▲ 0.0% | 1.86 ▲ 564.3% | 1.86 ▲ 0.0% | 2.95 ▲ 58.6% | 2.95 ▲ 0.0% | 5.83 ▲ 97.6% | 5.83 ▲ 0.0% | 4.56 ▼ 21.8% | 4.56 ▲ 0.0% | 5.85 ▲ 28.3% | 5.85 ▲ 0.0% | 6.93 ▲ 18.5% | 6.93 ▲ 0.0% | 0.84 ▼ 87.9% | 0.84 ▲ 0.0% | 9.22 ▲ 997.6% | 9.22 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 41 | 41 ▲ 0.0% | 41 ▲ 0.0% | 41 ▲ 0.0% | 41 ▲ 0.0% | 41 ▲ 0.0% | 41 ▲ 0.0% | 41 ▲ 0.0% | 41 ▲ 0.0% | 41 ▲ 0.0% | 45 ▲ 10.7% | 45 ▲ 0.0% | 45 ▲ 0.0% | 45 ▲ 0.0% | 45 ▲ 0.0% | 45 ▲ 0.0% | 45 ▲ 0.0% | 45 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | -3 | -3 ▲ 0.0% | -0 ▲ 87.7% | -0 ▲ 0.0% | 7 ▲ 1749.2% | 7 ▲ 0.0% | 0 ▼ 92.9% | 0 ▲ 0.0% | 50 ▲ 10644.2% | 50 ▲ 0.0% | 52 ▲ 3.8% | 52 ▲ 0.0% | 29 ▼ 45.2% | 29 ▲ 0.0% | 5 ▼ 83.2% | 5 ▲ 0.0% | 176 ▲ 3566.2% | 176 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 759 | 759 ▲ 0.0% | 900 ▲ 18.6% | 900 ▲ 0.0% | 977 ▲ 8.5% | 977 ▲ 0.0% | 1,081 ▲ 10.6% | 1,081 ▲ 0.0% | 1,285 ▲ 18.9% | 1,285 ▲ 0.0% | 1,574 ▲ 22.5% | 1,574 ▲ 0.0% | 1,804 ▲ 14.6% | 1,804 ▲ 0.0% | 219 ▼ 87.9% | 219 ▲ 0.0% | 2,473 ▲ 1029.6% | 2,473 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 47.65% | 47.65% | 41.20% | 41.20% | 32.74% | 32.74% | 30.50% | 30.50% | 36.27% | 36.27% | 33.10% | 33.10% | 30.66% | 30.66% | 28.71% | 28.71% | 32.51% | 32.51% | |
| Employee Cost % of RevenueDerived | 19.51% | 19.51% | 15.91% | 15.91% | 14.85% | 14.85% | 14.34% | 14.34% | 14.78% | 14.78% | 12.92% | 12.92% | 13.49% | 13.49% | 13.36% | 13.36% | 14.26% | 14.26% | |
| Other Cost % of RevenueDerived | 14.86% | 14.86% | 21.08% | 21.08% | 20.16% | 20.16% | 17.74% | 17.74% | 19.78% | 19.78% | 19.01% | 19.01% | 17.78% | 17.78% | 22.88% | 22.88% | 22.09% | 22.09% | |
| Interest Coverage (x)Derived | 2.16x | 2.16x | 11.32x | 11.32x | 18.93x | 18.93x | 38.00x | 38.00x | 25.35x | 25.35x | 31.49x | 31.49x | 34.30x | 34.30x | 38.19x | 38.19x | 20.81x | 20.81x |
MARKSANS PHARMA segment analysis : revenue and profit mix.
Disclosed business segments at MARKSANS PHARMA with their share of revenue and profit, switchable between consolidated and standalone reporting.
MARKSANS PHARMA discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for MARKSANS PHARMA.
Our AI distills the core fundamental drivers supporting MARKSANS PHARMA, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 34 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 13% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.15%.
MARKSANS PHARMA peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — MARKSANS PHARMA is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
MARKSANS PHARMA chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for MARKSANS PHARMA — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
MARKSANS PHARMA delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for MARKSANS PHARMA over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in MARKSANS PHARMA stood at 42.8% of traded volume, against a 20-day average of 41.8%.
MARKSANS PHARMA announcements: results, concalls, ratings, M&A.
Filings MARKSANS PHARMA sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
MARKSANS PHARMA files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 162 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Marksans Pharma Limited has informed the Exchange about Certificate under regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter and half…
Trading Window
Marksans Pharma Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
General Updates
Marksans Pharma Limited has informed the Exchange regarding opening of Special Window for Re-lodgment of Transfer Requests of Physical Shares
Copy of Newspaper Publication
Marksans Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding transfer of unclaimed dividend and equity shares of…
Analysts/Institutional Investor Meet/Con. Call Updates
Marksans Pharma Limited has informed the Exchange about Schedule of Investors Meet
Investor decks & rating reports.
MARKSANS PHARMA dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue MARKSANS PHARMA has declared, sequenced by announce and record date.
MARKSANS PHARMA corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About MARKSANS PHARMA: business, sector, key facts.
What MARKSANS PHARMA does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
MARKSANS PHARMA operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: MARKSANS, BSE: 524404.
Marksans Pharma Limited is a multinational pharmaceutical company with a global reach, operating in numerous countries including the United States, Canada, European nations, the United Kingdom, Australia, New Zealand, and other international markets. Their core business revolves around the research, development, manufacturing, marketing, and distribution of a wide array of pharmaceutical formulations.
The company's product portfolio spans a broad spectrum of therapeutic areas, addressing diverse health concerns. This includes pain management medications, treatments for upper respiratory infections, cardiovascular drugs, central nervous system medications, anti-diabetic agents, gastrointestinal remedies, analgesics, ear care products, skincare formulations, anticancer drugs, anti-ulcerative medications, anti-allergy treatments, antiviral drugs, dietary supplements, cardiac medications, dermatological products, antihistamines, antifungals, laxatives, and cold and cough remedies. This extensive range demonstrates Marksans' commitment to providing comprehensive healthcare solutions.
Marksans Pharma boasts a versatile manufacturing capability, producing a variety of dosage forms to cater to various needs and preferences. Their manufacturing processes encompass solid oral dosage forms such as tablets and hard gelatin capsules, as well as soft gels, essential oils, ointments, creams, and liquids. They also produce prescription drugs, highlighting their ability to serve both over-the-counter and prescription medication markets.
The distribution network of Marksans Pharma extends across various retail channels. Their products reach consumers through supermarkets, high street retailers, pharmacy chains, and wholesalers, ensuring widespread accessibility. This diverse distribution strategy contributes significantly to the company's market penetration and overall success.
Established in 1992 and headquartered in Mumbai, India, Marksans Pharma Limited has a long history in the pharmaceutical industry. Their global presence and diverse product offerings position them as a significant player in the international pharmaceutical market, consistently striving for innovation and expansion in their therapeutic areas and geographic reach.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about MARKSANS PHARMA (MARKSANS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of MARKSANS PHARMA (MARKSANS)?
The current share price of MARKSANS PHARMA (MARKSANS) is ₹294.45. Today, the stock has declined by ₹3.70 (1.24%), trading in a range of ₹291.25 to ₹298.00. The stock opened at ₹294.00 with a trading volume of 8,17,786 shares.
02Is MARKSANS PHARMA stock a good investment for long-term?
MARKSANS PHARMA can be considered for long-term investment based on several factors. The company has a market capitalization of ₹13,594.91 Cr., P/E ratio of 26.32, ROE of 18.2%, and ROCE of 19.33%. The dividend yield stands at 0.3%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of MARKSANS PHARMA stock?
The 52-week high price of MARKSANS PHARMA (MARKSANS) is ₹350.95, while the 52-week low is ₹155.00. Currently trading at ₹294.45, the stock is 89.97% above its 52-week low and 16.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy MARKSANS PHARMA stock at the current price?
Whether to buy MARKSANS PHARMA stock at ₹294.45 depends on multiple factors. The stock is currently trading with a P/E ratio of 26.32 and P/B ratio of 4.5. Today's performance shows a loss of 1.24%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of MARKSANS PHARMA and when is the next dividend?
MARKSANS PHARMA offers a dividend yield of 0.3%, which means for every ₹100 invested at the current price of ₹294.45, you can expect to receive approximately ₹0.30 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of MARKSANS PHARMA?
MARKSANS PHARMA's key financial metrics include: P/E Ratio: 26.32, P/B Ratio: 4.5, ROE: 18.2%, ROCE: 19.33%, Dividend Yield: 0.3%, EPS: ₹3.47, Book Value: ₹67.36, and Debt-to-Equity: 0. The company's market cap stands at ₹13,594.91 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is MARKSANS PHARMA stock performing today in the market?
MARKSANS PHARMA stock opened at ₹294.00 and is currently trading at ₹294.45, showing a decline of ₹3.70 (1.24%). The intraday high is ₹298.00 and low is ₹291.25. The trading volume stands at 8,17,786 shares, indicating moderate market participation today.
08What is the P/E ratio of MARKSANS PHARMA and what does it indicate?
MARKSANS PHARMA has a Price-to-Earnings (P/E) ratio of 26.32, which means investors are willing to pay 26.32 for every ₹1 of earnings. With an EPS of ₹3.47, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about MARKSANS PHARMA (MARKSANS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.